ClinicalTrials.gg
Not yet recruitingNCT07561658Updated Nov 20, 2026

TelePharm PrEP/PEP

An interventional study of Telehealth delivery of pharmacy PrEP/PEP and Standard pharmacy PrEP/PEP delivery in HIV, sponsored by Fred Hutchinson Cancer Center. Not yet recruiting at 1 site in Kenya. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Prevention

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,580
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

In this study, the investigators will evaluate whether introducing a remote nurse to screen, counsel, and guide clients through HIV self-testing (via a telehealth platform) and support interested clients (via SMS) between pharmacy visits increases PrEP/PEP initiations and continuation compared to standard PrEP/PEP delivery by pharmacy providers. The investigators hypothesize that pharmacy PrEP/PEP services delivered with telehealth support will result in better service utilization and implementation outcomes compared to standard delivery and be cost-effective to implement.

Read the detailed description

Participating study pharmacies will be 1:1 randomized 24 pharmacies (n=1,580 clients ≥15 years) to either: 1) telehealth support, where a remote nurse screens, counsels, and guides clients through HIV self-testing (HIVST) and, between visits, communicates with interested clients via 2-way SMS, or 2) standard delivery, where the pharmacy provider performs all delivery tasks and clients are not given additional support. The primary outcomes are PrEP/PEP initiation and continuation, assessed 180 days following clients' first pharmacy PrEP/PEP visit.

02

Conditions studied

  • HIV

Keywords

  • Kenya
  • pre-exposure prophylaxis (PrEP)
  • post-exposure prophylaxis (PEP)
  • Pharmacy
03

In context

Lead sponsor

Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.

Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pharmacies

  • Registered with the Pharmacy and Poisons Board (PPB)
  • Must have at least one full-time licensed pharmacist or pharmaceutical technologist on staff
  • Must have a private room where testing and PrEP/PEP counseling can occur
  • >3 km from other study pharmacies
  • Willing to participate in research activities, including 2-day training for pharmacy providers
  • Willing to share pharmacy records with us
  • Sells HIVST kits that are WHO certified.

Pharmacists/remote nurses

  • ≥ 18 years old
  • Licensed pharmacist, pharmaceutical technologist, or nurse
  • Willing to provide PrEP and PEP services, including HIV testing and associated counseling services
  • Willing to complete training on PEP/PrEP service delivery at pharmacies, including certification for rapid diagnostic testing
  • Able and willing to provide

Clients

  • ≥ 15 years old
  • Interested in being screened for PrEP or PEP
  • Meets all criteria to be eligible for pharmacy-delivered PrEP or PEP on the Prescribing Checklist, including being at risk for HIV and not having any medical conditions that might contraindicate PrEP/PEP safety
  • Able and willing to provide informed consent

Exclusion criteria

Exclusion Criteria:

Clients

  • Unwilling to provide a phone number at which an RA can reach them for completing surveys and communicate important study-related information
  • Currently enrolled in any other vaccine or prevention trial
  • Have a condition that would preclude provision of , make study participation unsafe, complicate interpretation of outcome data, or otherwise interfere with achieving study objectives
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,580 participants (estimated)

Study arms

  • Experimental
    Telehealth support

    Pharmacy provider-led PrEP/PEP delivery, with telehealth support from remote nurses for counseling and testing at or between pharmacy visits (includes guided HIV self-testing and optional 2-way SMS with remote nurses).

    Other: Telehealth delivery of pharmacy PrEP/PEP

  • Active comparator
    Standard delivery

    Pharmacy provider-led PrEP/PEP delivery, without telehealth support from remote nurses for counseling and testing at or between pharmacy visits (includes guided HIV self-testing).

    Other: Standard pharmacy PrEP/PEP delivery

Interventions

  • OtherTelehealth delivery of pharmacy PrEP/PEP

    Remote nurses screen, counsel, and guide HIV self-testing for pharmacy clients; pharmacy providers dispense PrEP or PEP. SMS support from remote nurses available between pharmacy visits.

  • OtherStandard pharmacy PrEP/PEP delivery

    Pharmacy provider screen, counsel, and guide HIV self-testing for pharmacy clients, and dispense PrEP or PEP. SMS support not available between pharmacy visits.

06

What researchers measure

Primary outcomes

  1. PrEP/PEP initiation

    Pharmacy-level; count outcome: # of unique clients dispensed any form of PrEP or PEP over the implementation period

    Time frame: 18 months post implementation

  2. PrEP/PEP continuation

    Pharmacy-level; count outcome: # of unique clients that refilled PrEP, transitioned from PEP-to-PrEP, or were dispensed PEP or on-demand PrEP 1+ times over the implementation period

    Time frame: 18 months post implementation

Secondary outcomes

  1. PrEP initiation

    Pharmacy-level; count outcome: # of unique clients dispensed any form of PrEP over the implementation period

    Time frame: 18 months post implementation

  2. PEP initiation

    Pharmacy-level; count outcome: # unique clients dispensed any form of PEP over the implementation period

    Time frame: 18 months post implementation

  3. PrEP/PEP use

    Pharmacy-level; count outcome: # of unique clients who swallowed any PrEP or PEP during the implementation period

    Time frame: 1.5 and 6 months from initiation

  4. PrEP use

    Pharmacy-level; count outcome: # of unique clients who swallowed any PrEP during the implementation period

    Time frame: 1.5 and 6 months from initiation

  5. PEP use

    Pharmacy-level; count outcome: # of unique clients who swallowed any PEP during the implementation period

    Time frame: 1.5 and 6 months from initiation

  6. PrEP refill

    Pharmacy-level; count outcome: # of unique clients who refilled PrEP after initiating PrEP

    Time frame: 18 months post implementation

  7. Repeat PEP

    Pharmacy-level; count outcome: # unique clients who were dispensed PEP or PEP-in-pocket after initiating PEP

    Time frame: 18 months post implementation

  8. PEP-to-PrEP

    Pharmacy-level; count outcome: # unique clients who were dispensed PrEP after initiating PEP (any form) over the implementation period

    Time frame: 18 months post implementation

  9. Engaged with 1+ product

    Pharmacy-level; count outcome: # of unique clients that were dispensed more than one HIV prevention product (oral PrEP, injectable PrEP, PEP, etc) over the implementation period

    Time frame: 18 months post implementation

  10. On-demand PrEP use

    Pharmacy-level; count outcome: # of unique clients who were dispensed and swallowed any on-demand PrEP over the implementation period

    Time frame: 6 months from initiation

  11. PEP-in-Pocket use

    Pharmacy-level; count outcome: # of unique clients who were dispensed and swallowed any PEP-in-Pocket over the implementation period

    Time frame: 6 months from initiation

  12. Product choice

    Individual-level; binary outcome: % of total PrEP/PEP clients that were dispensed each type of product (e.g., oral PrEP, on- demand PrEP, PEP, DVR, etc).

    Time frame: 18 months post implementation

  13. PrEP adherence

    Individual-level; binary outcome: % PrEP initiators (excluding on-demand) with optimal TFV-DP concentration in DBS

    Time frame: 1.5 months from initiation

  14. Reach

    Individual-level; binary outcome: % of PrEP/PEP clients in different populations of interest (e.g., men; youth \<25 years); with separate evaluations by product type

    Time frame: 18 months post implementation

  15. Efficiency

    Pharmacy-level; continuous outcome: Avg. duration (per visit \& annually) of pharmacy providers' encounter per PrEP/PEP client, and clients' PrEP/PEP visit duration

    Time frame: 18 months post implementation

  16. Fidelity

    Individual-level; binary outcome: % of clients that received PrEP/PEP services as intended (e.g., correct quantity of drugs)

    Time frame: 1.5 months post initiation

  17. Sustainment

    Pharmacy-level; count outcome: Volume of unique PrEP/PEP clients served in the past 6 months, assessed at 24 months

    Time frame: 24 months post implementation

  18. Acceptability

    Individual-level; cont, binary outcome: # of unique client who find the study components acceptable; % of providers, including remote nurses, indicating acceptability; Also assessed in Aim 2 (described below)

    Time frame: 24 months post implementation

Other outcomes

  1. Time to use (for on-demand PrEP) at 1.5 months

    Pharmacy-level; continuous outcome: Avg. duration (in days) from on-demand PrEP dispensing to use, among on-demand clients

    Time frame: 1.5 months

  2. Time to use (for on-demand PrEP) at 6 months

    Pharmacy-level; continuous outcome: Avg. duration (in days) from on-demand PrEP dispensing to use, among on-demand clients

    Time frame: 6 months

  3. STI diagnosis

    Individual-level; binary outcome: % of PrEP/PEP clients with a syndromic STI diagnosis (at any pharmacy PrEP/PEP visit)

    Time frame: 18 months post implementation

  4. Other drugs dispensed

    Pharmacy-level; binary outcome: % of PrEP/PEP clients dispensed other drugs (e.g., hypertension, contraception) at their visit

    Time frame: 18 months post implementation

  5. HIV incidence

    Pharmacy-level; binary outcome: % of PrEP/PEP clients who tested positive

    Time frame: 18 months

  6. HIV risk

    Inidiviudal-level; binary outcome: % of PrEP/PEP clients reporting specific behaviors (i.e., multiple sex partners)

    Time frame: 18 months post implementation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Participant-level pharmacy record and research data will be shared through deposition of the data in an open-access public repository (Dryad). In addition to sharing the study data publicly, data dictionaries and other tools supporting use of the data will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified pharmacy record and research data from this study will be deposited in the Dryad data repository within 12 months of publication.

Access criteria: The study data will be accessible through the Dryad data repository. For all publications, a dataset will be created that is assigned a digital object identifier (DOI), which will be referenced in the publication so the research community can easily find and access the data, if interested. The Dryad repository can also be searched by topic, institution, and investigator name, which should make it easy for other interested parties to find and access the study data. Any study data that cannot be shared via Dryad, will be made available through a formal request to the PIs. We will share data and supporting documentation upon request to outside investigators, after scientific review, IRB approval, and obtaining relevant Data Use Agreements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Mar 2028, 13 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Feb 2027, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 1, 2026
StartEst.
Feb 1, 2027was Oct 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Feb 1, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Oct 1, 2026→Feb 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07561658
Collaborators
Kenya Medical Research Institute, ClickMedix LLC, National Institute of Mental Health (NIMH)
Responsible party
Katrina Ortblad (Assistant Professor, Fred Hutchinson Cancer Center) — Principal investigator
First posted
May 1, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Katrina F Ortblad
Contact
kortblad@fredhutch.org
206-667-7267
Kendall V Harkey
study chair · Fred Hutch Cancer Center
Rachel C Malen
study chair · Fred Hutch Cancer Center
Katrina F Ortblad
principal investigator · Fred Hutch Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion